Intercept Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intercept Pharmaceuticals, Inc.
Analysts say the cirrhosis-reversing benefit seen with Akero’s efruxifermin portends well for the entire class, and that 89bio might differentiate on safety, tolerability and dosing frequency.
Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.